Differentiating de novo AML with BCR::ABL1 from the myeloid blast phase of CML can be challenging and requires a thorough evaluation of the clinical history, morphology, and cytogenetic/molecular features. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.